MiR-200a prevents renal fibrogenesis through repression of TGF-β2 expression

Diabetes

Volumn 60, Issue 1, 2011, Pages 280-287

  Wang, Bo ^a   Koh, Philip ^a   Winbanks, Catherine ^b   Coughlan, Melinda T ^a   McClelland, Aaron ^a   Watson, Anna ^a   Jandeleit Dahm, Karin ^a   Burns, Wendy C ^a   Thomas, Merlin C ^a   Cooper, Mark E ^a   Kantharidis, Phillip ^a  

^a JDRF Danielle Alberti Memorial Centre for Diabetes Complications   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; APOLIPOPROTEIN E; BETA ACTIN; BIOLOGICAL MARKER; COLLAGEN TYPE 1; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; LUCIFERASE; MESSENGER RNA; MICRORNA; MICRORNA 141; MICRORNA 200A; RECEPTOR BLOCKING AGENT; SB 432542; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; UVOMORULIN;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FEEDBACK SYSTEM; FIBROGENESIS; GENE EXPRESSION REGULATION; GENE REPRESSION; GENETIC TRANSFECTION; KIDNEY FIBROSIS; KIDNEY PROXIMAL TUBULE; KNOCKOUT MOUSE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES;

3' UNTRANSLATED REGIONS; ANIMALS; CELL LINE; DIABETIC NEPHROPATHIES; DOWN-REGULATION; EPITHELIAL CELLS; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION; GENE SILENCING; GENES, REPORTER; HUMANS; KIDNEY TUBULES; LUCIFERASES; MESODERM; MICE; MICRORNAS; POLYMERASE CHAIN REACTION; RATS; RNA; SMAD3 PROTEIN; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

EID: 78751516162     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-0892     Document Type: Article

References (26)

1. Gregory PA, Bracken CP, Bert AG, Goodall GJ. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008;7:3112-3118
2. Jiang X, Tsitsiou E, Herrick SE, Lindsay MA. MicroRNAs and the regulation of fibrosis. FEBS J 2010;277:2015-2021
3. Hendrickson DG, Hogan DJ, McCullough HL, Myers JW, Herschlag D,Ferrell JE, Brown PO. Concordant regulation of translation and mRNA abundance for hundreds of targets of a human microRNA. PLoS Biol 2009;7:e1000238
4. Burns WC, Twigg SM, Forbes JM, Pete J, Tikellis C, Thallas-Bonke V, Thomas MC, Cooper ME, Kantharidis P. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006;17:2484-2494
5. Fan JM, Ng YY, Hill PA, Nikolic-Paterson DJ, Mu W, Atkins RC, Lan HY. Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int 1999;56:1455-1467
6. Yu L, Border WA, Huang Y, Noble NA. TGF-beta isoforms in renal fibrogenesis. Kidney Int 2003;64:844-856
7. Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP, Cardell EL, Doetschman T. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 1997;124:2659-2670
8. Sims-Lucas S, Caruana G, Dowling J, Kett MM, Bertram JF. Augmented and accelerated nephrogenesis in TGF-beta2 heterozygous mutant mice. Pediatr Res 2008;63:607-612
9. Hill C, Flyvbjerg A, Grønbaek H, Petrik J, Hill DJ, Thomas CR, Sheppard MC, Logan A. The renal expression of transforming growth factor-betaisoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology 2000;141:1196-1208
10. Hill C, Flyvbjerg A, Rasch R, Bak M, Logan A. Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol 2001;170:647-651
11. Ledbetter S, Kurtzberg L, Doyle S, Pratt BM. Renal fibrosis in mice treated with human recombinant transforming growth factor-beta2. Kidney Int 2000;58:2367-2376
12. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593-601
13. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998;17:3091-3100
14. Lassila M, Jandeleit-Dahm K, Seah KK, Smith CM, Calkin AC, Allen TJ, Cooper ME. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 2005;16:363-373
15. Terai K, Mizukami K, Okada M. Comparison of chronic renal failure rats and modification of the preparation protocol as a hyperphosphataemia model. Nephrology (Carlton) 2008;13:139-146
16. Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, Barit D, Coughlan MT, Drew BG, Lancaster GI, Thomas M, Forbe s JM, Nawroth PP, Bierhaus A, Cooper ME, Jandeleit-Dahm KA. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008;57:2461-2469
17. Wang B, Herman-Edelstein M, Koh P, Burns W, Jandeleit-Dahm K, Watson A, Saleem M, Goodall GJ, Twigg SM, Cooper ME, Kant haridis P. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes 2010;59:1794-1802
18. Christoffersen NR, Silahtaroglu A, Orom UA, Kauppinen S, Lund AH. miR-200b mediates post-transcriptional repression of ZFHX1B. Rna 2007; 13:1172-1178
19. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelialmesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008;283:14910-14914
20. Paterson EL, Kolesnikoff N, Gregory PA, Bert AG, Khew-Goodall Y, Goodall GJ. The microRNA-200 family regulates epithelial to mesenchymal transition. ScientificWorldJournal 2008;8:901-904
21. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008;9:582-589
22. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006;69:213-217
23. Kalluri R. EMT: when epithelial cells decide to become esenchymal-like cells. J Clin Invest 2009;119:1417-1419
24. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002;110:341-350
25. Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, Atkins RC, Osicka T, Jerums G, Cooper ME. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001;108: 1853-1863
26. Hurteau GJ, Carlson JA, Spivack SD, Brock GJ. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 2007;67:7972-7976